Sphere-9 Can Ablate VT in Europe While Its US Pivotal Is Still Enrolling
Medtronic can sell Sphere-9 into ventricular tachycardia in Europe while the trial meant to prove it works in the US is only now enrolling.
The Beats
Analysis
The Briefs
Sphere-9 Can Ablate VT in Europe While Its US Pivotal Is Still Enrolling
The FDA Approved Orzeyful and Handed the Approval Date to the DEA
NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision
Argenx’s $2.2 Billion Bought a Phase 1b With Ten Patients on Placebo
Medicover Calls India a Distraction. KKR Just Paid 5.4x Revenue for It.
